Reflecting on BIO Digital 202105 Jul 2021
The BIO Digital 2021 convention attracted thousands of biotech leaders and innovators from around the world with the objective to transform the future of science. By establishing new collaborations and partnerships, the BIO Digital convention enables transformational and disruptive products and therapies to market, helping solve some of our world’s most critical health challenges. Experts from within Albumedix attended last month and have gathered their thoughts and reflections below.
COVID-19 and Adaptive Trials
It would be practically impossible to reflect without considering the impact of the COVID-19 pandemic. We have seen the scientific community pull together in an unprecedented manner, for example showing us that it is possible to speed up clinical trials. Adaptive trial designs allow the scientific community to move toward a more efficient process and for informative outcomes to be achieved with no impact on scientific rigor. Several sessions at BIO Digital 2021 reflected on the new opportunities with adaptive trials, and ways to enhance the R&D process to ultimately get the right treatments to patients in a timely manner.
A priority of the BIOEquality Agenda was to promote health equity and eliminate systemic inequalities in the biotech ecosystem. As such, several sessions of the Sustainable & Equitable Clinical Development Summit discussed new ways to engage with patient groups in novel clinical trial designs, and business strategies to reach underrepresented communities. There was a common force of healthcare leaders and executives at BIO Digital 2021 to focus on lessons learned and provide new inclusive solutions for the future.
The future of scale-up and commercialization?
As we know, times are changing and we all need to evolve to enable a faster pace to reach new markets; as such, balancing speed, risk, and future needs is a known challenge in the biotechnology sector. At the BIO Digital 2021, we could learn new ways to accelerate post-discovery to IND milestone timelines, leading to faster first-in-human trials and construct strong foundations for future scaleup and commercialization. Experts discussed trade-offs and the long-term implications of business choices initially made. Plus, there was an outlook at other critical considerations that impact timelines and commercialization, including the use of robust platform process design, high-throughput automation technologies, optimized workflows, and life-cycle approaches such as expression systems that enable streamlined procedures.
As usual, the BIO One-On-One Partnering was a success and connected Albumedix with several current and future associates, proving once again the BIO convention track-record of facilitating critical business connections in a virtual environment and ensuring that global biotech’s achieve their goals. If you were unable to participate this year but would like to book a follow-up meeting with Albumedix, please contact us today.